|
|
||||||||
Articles |
Chesterfield Royal Hospital NHS Foundation Trust, Charles Clifford Dental Hospital, Sheffield, UK
Orthodontic Division, The Queens University of Belfast, UK
Chesterfield Royal Hospital NHS Foundation Trust, UK
Address for correspondence: Jonathan Sandler, Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield Rd, Calow, Chesterfield, S44 5BL, UK., Email: jonsandler{at}aol.com
| Abstract |
|---|
|
|
|---|
Key words: Medical disorders, orthodontics, guidelines
| Introduction |
|---|
|
|
|---|
This article examines aspects of some of the conditions that are of relevance to orthodontic practice. A comprehensive medical history should be taken and regularly updated. Case notes should alert the clinician to the patients medical status. All medical conditions should be accurately understood before any treatment is planned and this may involve seeking guidance from the patients physician. Patients should be well informed of all the options and made aware that any orthodontic treatment has been planned with their best interests at heart. It should be highlighted they are not being penalized for their medical condition.2
The importance of excellent oral hygiene should be emphasized to all patients considering a course of orthodontics.
| Cardiovascular system |
|---|
|
|
|---|
The lack of evidence from human models and changing clinical profile of IE has led several authorities to update their guidelines in recent years (Table 1
). Most authorities across Europe and from the United States of America recommend the use of prophylaxis prior to invasive procedures in high-risk patients.5
–8
|
Although prophylactic regimes suggest single dose administration, from which non-fatal side effects are usually minor, there is a risk of fatal anaphylaxis, which affects 12–25 people per million.14
Orthodontic considerations in patients with cardiovascular disorders
|
Haematology and patients with bleeding problems
Disorders of the blood, whether acquired or inherited can affect the management of orthodontic patients. Mild bleeding disorders are not problematic to the orthodontist but patients with severe disorders may require more care.
A history of a clinically significant episode is one that
Inherited coagulopathies – deficiencies in clotting factors
Haemophilia is a common example of a clotting factor deficiency. Haemophilia A is a sex-linked disorder due to a deficiency of Factor VIII. When the Factor VIII level is less than 1% of normal, the condition is classified as severe.20
Other bleeding disorders include Haemophilia B or Christmas disease (factor IX deficiency) and von Willebrands disease (defects of von Willebrands factor).
As well as problems with bleeding, these patients may be infected with HIV or hepatitis viruses because of the transfusion of infected blood or blood products before 1985. The methods of screening and manufacture have improved, but they do not rule out the risk of virus transmission entirely. The UK Department of Health (DoH) carried out a risk assessment concluding that all recipients of UK sourced plasma-derived coagulation factor concentrates used in the period 1980–2001 should be regarded as being at risk of developing variant Creutzfeldt-Jakob disease (vCJD) for public health purposes.21
Risk assessments have been carried by both the DoH and the World Federation of Haemophilia which could not identify any person with haemophilia who has developed vCJD.22
,23
Moreover, they concluded that routine dental treatment including minor oral surgery is unlikely to pose a cross-infection risk.
Orthodontic considerations in patients with bleeding disorders
|
Sickle cell anaemia
This is a genetic disorder that is characterized by a haemoglobin gene mutation (HbS as opposed to HbA). Deoxygenation, for example during anaesthesia induces the red cells to deform into a sickle shape. This restricts their movement through capillaries and hence deprives the tissues of oxygen and in conscious patients causes intense pain. The disease is chronic and life expectancy is shortened to about 45 years.29
Sickle cell trait is the term given to patients who inherit one of the genes of sickle cell disease but without developing the recurrent symptoms. It is not benign and can also have symptoms due to comorbidity and conditions that can lead to overheating, dehydration and sickling.
Sickle cell anaemia is more common in people of African origin where malaria is common but it also occurs in people of Asian and West Indian descent.30
Treatment ranges from NSAIDs for milder vaso-occlusive crises to IV opioids.31
Acute chest crises are treated with antibiotics and blood transfusions to reduce the percentage of HbS in the blood. The risks of blood transfusions have been discussed above. Tetracycline may need to be given as an alternative to amoxicillin or flucloxacillin when the child develops multiple drug sensitivity. Chemotherapy32
and bone marrow transplants have also been advocated and these treatments come with their own list of orthodontic considerations.
Oral manifestations of sickle cell disease include enamel hypoplasia in the form of white spots on the tooth surface, dentinal hypomineralization, delayed tooth eruption, pale lips and oral mucosa and glossitis. Radiographic signs include osteoporosis and parallel trabeculae amidst teeth but not in edentulous areas.33
Mandibular osteomyelitis in the absence of other problems can occur due to the limited blood supply. Vaso-occlusive crises can predispose the patient to pain and paraesthesia of the inferior alveolar nerve and the lower lip.
Orthodontic considerations in patients with sickle cell anaemia
|
Leukaemia
Leukaemia is divided into acute and chronic forms. Acute lymphoblastic leukaemia (ALL) is the commonest presentation in children accounting for 25% of all childhood tumours. The prognosis in children with ALL is better than that for adults for whom the long-term survival is low. Acute myeloblastic leukaemia (AML) is more common in adults than children and the prognosis is poor. The treatment for acute leukaemia includes chemotherapy or bone marrow transplantation (BMT). Total body irradiation (TBI) and immunosuppression are used to prevent graft-versus-host disease after BMT.
Chronic leukaemia involves the proliferation of more mature cells than those found in acute leukaemia. The prognosis is better and adults are more commonly affected than children. Chronic lymphocytic leukaemia (CLL) is more common and patients tend to be asymptomatic. Chronic myeloid leukaemia (CML) affects adults of a younger age group than CLL. The main signs of the chronic leukaemia tend to be splenomegaly and lymph node enlargement. Treatment is with chemotherapy and radiotherapy.
The sequelae of treatment may be immediate or may occur several months after treatment. These effects can be caused by the malignancy itself, by the treatment including chemotherapy, radiotherapy and supportive care such as transfusions, antibiotics and immunosuppressive treatment. The degree to which an individual is affected is related to the age at which the disease is diagnosed and treated and the type and intensity of the treatment. The growth rate generally declines in children during treatment for leukaemia. Soon after treatment the normal growth rate is resumed and catch up growth is sometimes seen. Growth hormone therapy has the capacity to improve the height velocity.36
Bone density is frequently reduced in long-term survivors of childhood malignancies.37
They also show acute and long-term complications in the oral cavity and in dental and craniofacial development. The most common dental disturbances are arrested root development with V-shaped roots, premature apical closure, microdontia, enamel disturbances and aplasia.38
A common side effect of radiation is salivary dysfunction leading to xerostomia. Craniofacial disturbances were demonstrated by a case controlled study of 17 children treated for ALL with allogeneic BMT and TBI. The ALL group had reduced vertical dimensions of the face, alveolar processes as well as reduced sagittal dimensions of the jaws, characterized by mandibular retrognathism.39
Orthodontic considerations in patients with leukaemia
|
| Respiratory system |
|---|
|
|
|---|
Asthma
Approximately 300 million people around the world have asthma, and it has become more common in both children and adults globally in recent years.45
The severity varies from mild to severe. In moderate cases episodes are severe but the patients are symptom free between attacks. In severe asthma the attacks are severe and the child is never asymptomatic and growth and lung function can be affected.
There has been a tentative link between orthodontically induced external root resorption and patients with asthma.46
This increased prevalence of resorption was confined to mild root blunting and the researchers concluded that longevity or function of posterior teeth would not be adversely affected. Nonetheless patients should be informed of this risk prior to treatment.
Cystic fibrosis
Cystic fibrosis (CF) is the most common life limiting, childhood-onset, autosomal recessive disorder among people of European heritage. It affects the exocrine glands of the lungs, liver, pancreas and intestines, causing progressive disability due to multisystem failure. The cells are relatively impermeable to chloride ions and thus salt rich secretions are produced. The mucous is viscid and blocks glands of the respiratory and digestive systems. There is a non-productive cough that leads to acute respiratory infection, bronchopneumonia, bronchiectasis, and pancreatic insufficiency. Diabetes mellitus may be a complication and patients may have cirrhosis of the liver.47
,48
There is no cure for CF. Most individuals with CF die young: many in their 20s and 30s from lung failure; however, with advances in medical treatments, the life expectancy of a person with CF is increasing to ages as high as 40 or 50.49
Heart and lung transplantation are often necessary as CF worsens. Oral effects include hypoplastic enamel and delayed eruption. In the 1970s there were several reports of tetracycline staining of teeth but alternative medications are now used.50
A side effect of antibiotic treatment is the lower prevalence of dental disease.51
Relevance of drugs in respiratory disorders
The chronic use of corticosteroid inhalers can lead to localized lowered resistance to opportunistic infections. As a result of this oro-pharyngeal candidal infection may occur.52
To avoid this complication, patients should be advised to rinse and gargle with water after the use of their inhaler especially if wearing removable acrylic appliances.53
Candidiasis can be treated with topical antifungal agents such as nyastatin. Additionally the regular use of inhaled corticosteroids can predispose the patient to an adrenal crisis if subjected to stress. The need for steroid cover is discussed in the general section on drugs and orthodontic treatment.
Beta-adrenergic agonist bronchodilators such as sal-butamol, antimuscarinic bronchodilators, cromoglycates and antihistamines can all produce dry mouth, taste alteration and discolouration of teeth.
Orthodontic considerations in patients with respiratory disorders
|
| Neurological disorders |
|---|
|
|
|---|
Epilepsy
Epilepsy is a common symptom of an underlying neurological disorder. The seizures can take a variety of forms and epilepsy is considered to be active if a person has had a seizure within the last 2 years or is taking anti-epileptic medication.56
Brain damage due to injury, infection, birth trauma or a cerebrovascular accident accounts for 25% of cases. The other 75% of cases have no identifiable cause but there is a familial trend. Epilepsy can develop in some genetic syndromes such as Downs syndrome57
or in Sturge-Weber syndrome.58
The risk of developing epilepsy is 2–5% over a lifetime. The prevalence of active epilepsy is between 5 and 10 people per 1000 of the population.59
The condition is more common in men and the incidence is high in the first two decades of life, and then reduces before increasing after the age of 50 years as a result of cerebrovascular disease.56
Hyperventilation, fever, photic stimulation, withdrawal or poor lack of compliance with anticonvulsants, lack of sleep, over-sedation, emotional upset and some medications such as antihistamines can stimulate attacks.
Both the condition and the medical management can affect oral health. Phenytoin was once the first choice in managing epilepsy in younger people but this has fallen out of favour because of its many side effects. These include nausea, mental confusion, acne, hirsutism, hepatitis, erythema multiforme and gingival overgrowth. However, the orthodontist may still encounter patients taking phenytoin. Alternatives such as carba-mazepine also have oral side effects including oral ulceration, xerostomia, glossitis and stomatitis.56
Prevention of oral disease and carefully planned dental and orthodontic treatment are essential to the well being of patients with epilepsy.
Other forms of treatment for epilepsy such as surgery are unlikely to have implications for orthodontic care.
Orthodontic considerations in patients with epilepsy
|
Multiple sclerosis (MS)
MS is a complex neurological condition that occurs as a result of damage to the myelin sheathes within the central nervous system. The damaged areas result in inflammation and interference in both sensory and motor nerve transmission.
MS is the most common cause of severe disability among young adults in the UK. It has an incidence of 0.1% (1 : 1000) in the general population.64
The diagnosis of MS is usually made between the ages of 20 and 40 years. It is more common in women than men with a ratio of 3 : 2.65
The prognosis depends on the subtype of the disease. The life expectancy of patients is nearly the same as that of the unaffected population, and in some cases a near-normal life is possible.
Subtypes of MS
|
The aetiology of MS is not understood and various environmental factors such as viruses, climatic factors have been implicated. It is not an inherited condition but there is a familial link.
The main symptoms relevant to oral care include pain and numbness of varying severity in the facial and oral tissues. The arms and hands can also be affected challenging the patients ability to carry out effective oral hygiene. Trigeminal neuralgia is atypical in that patients are younger, the pain may be bilateral and unstimulated. Indeed trigeminal neuralgia in people under 40 can be indicative of MS. Orthodontists should be aware of this and refer affected individuals for a neurological assessment.
Transient spasticity occurs when opposing muscles contract or relax at the same time leading to muscle stiffness, lack of coordination, clumsiness, muscle spasm and related pain. This can interfere with the safe delivery of orthodontic treatment and treatment should be delivered until the individual is in remission. Some patients also suffer from a tremor making satisfactory oral hygiene problematic.
There is no cure for MS. The focus of treatment is on the prevention of disability and maintenance of quality of life. Drugs, physical treatments and psychological techniques are used. Steroids are often used to help a person over a severe relapse. A plethora of other drugs can be prescribed, several of which can cause dry mouth, ulceration, gingival hyperplasia amongst other symptoms.66
Orthodontic considerations in patients with MS
|
| Liver disease |
|---|
|
|
|---|
The main effects of liver disease can be categorized into:
Infections
Viral hepatitis is undoubtedly of importance to the orthodontist. Hepatitis B (HBV), hepatitis C (HCV) and hepatitis D are blood borne and can be transmitted via contaminated sharps and droplet infection. Aerosols generated by dental hand pieces could infect skin, oral mucous membrane, eyes or respiratory passages of dental personnel and patients. The main orthodontic procedures to result in aerosol generation are removal of enamel during interproximal stripping, removal of residual cement after debonding, and prophylaxis.68
HBV has an incubation period of 6 weeks to 6 months and a small number of infected persons can progress to the carrier state associated with chronic active hepatitis and eventually cirrhosis. Hepatitis B Surface Antigen (HBsAg) is the first sign of infection. Antibody to HBsAg is associated with protection from infection. Hepatitis B Core Antigen (HBcAg) is detected by the development of an antibody to it. If the person is HBsAg negative but HBcAg positive they are infective. Hepatitis B e Antigen is only found if HBsAg is present and is an indication of infectivity.
Orthodontic considerations in patients with liver disease
|
| Endocrine conditions |
|---|
|
|
|---|
Type 1 DM, (insulin dependent, IDDM or juvenile-onset diabetes) results from defects in insulin secretion. The onset is usually before adulthood and accounts for approximately 5–15% of all people with DM. Type 1 DM occurs more frequently in people of European origin than non-European origin. It is life threatening if not treated with exogenous insulin.
Type 2 DM (non-insulin dependent NIDDM or mature-onset diabetes) develops as a result of defects in insulin secretion, insulin action or both. There is a link with being overweight. Type 2 DM usually appears in people over the age of 40, although in South Asian and African-Caribbean people often appears after the age of 25.71
However, recently, more children are being diagnosed with the condition, some as young as seven.72
This form of DM is also more prevalent in less affluent populations. It accounts for 85–95% of all cases of DM. It is not usually life threatening but chronic complications can affect the quality of life and reduce life expectancy.
Gestational diabetes is similar to type 2 DM in that it involves insulin resistance; the hormones of pregnancy can cause insulin resistance in women genetically predisposed to developing this condition. Gestational diabetes typically resolves with delivery of the child, however types 1 and 2 diabetes are chronic conditions.
The prevalence of DM is increasing in the UK and worldwide. The World Health Organisation predicts that the global prevalence of type 2 DM will increase from 135 million in 1995 to 300 million in 2025.73
DM is progressive and has potentially harmful consequences for health. Strict blood glucose control, lowering of blood pressure, together with a healthy lifestyle improves well being and protects against long term damage to the eyes, kidneys, nerves, heart and major arteries.74
Oral complications include: xerostomia, burning mouth and/or tongue, candidal infection, altered taste, progressive periodontal disease, dental caries, acetone breath, oral neuropathies, parotid enlargement, sialosis and delayed wound healing. These complications can occur even when the blood glucose is well controlled due to impaired neutrophil function but are all more severe in uncontrolled DM.
Orthodontic considerations in patients with DM
|
| Renal disorders |
|---|
|
|
|---|
CRF occurs after progressive renal damage. The symptoms and signs vary and can affect diverse body systems. Bone disease or renal osteodystrophy is an almost universal feature of CRF. Calcium metabolism is compromised by an elevated parathyroid hormone and by disruption in vitamin D metabolism. This results in secondary hyperparathyroidism. Renal disease also causes anaemia and marrow fibrosis leads to a reduced platelet count and poor platelet function. Haemostasis is impaired to varying degrees in patients with CRF.
Initially treatment is conservative with dietary restriction of sodium, potassium and protein. As the disease progresses dialysis or transplantation are required. Many patients are prescribed steroids to either combat renal disease or to avoid transplant rejection. Immunosuppressant drugs such as cyclosporine and calcium channel antagonists such as nifedipine are also taken to prevent transplant rejection. Immunosuppressants predispose the patients to infections. These drugs can also cause drug induced gingival overgrowth as discussed in the section on drugs and orthodontic treatment.
In children CRF leads to decreased growth and sometimes delayed eruption and enamel hypoplasia.
Orthodontic considerations in patients with renal disorders
|
| Musculoskeletal system |
|---|
|
|
|---|
JIA is classified according to the type of onset of the disease and the number of joints affected during the first 4–6 months: pauciarthritis or oligoarthritis denotes four or less joints being involved and polyarthritis when five or more joints are involved. JIA can be of varying severity with localized and/or systemic complications, including functional impairment of the affected joints. This may result in disturbances in growth and developmental anomalies. There is remission of the disease in adolescence, which happens for 70% of patients.82
The temporomandibular joint (TMJ) is affected in 45% of cases with JIA.83
The diagnosis of TMJ involvement is more difficult than the other joints as the signs and symptoms are missing or weak.84
Hence patients are most often seen when extensive changes have occurred. This can lead to the development of condylar hypoplasia, restricting mandibular growth resulting in mandibular retrognathism. JIA patients commonly present with skeletal Class II and open bite malocclusions.85
Mandibular asymmetry is seen in cases with unilateral TMJ involvement.
Early orthodontic intervention facilitates both the skeletal and the occlusal rehabilitation. The prevalence of dental caries and periodontal disease is higher in adolescents with JIA cases. This has been credited to a combination of factors including difficulties in executing good oral hygiene, unfavourable dietary practices and side effects from the long-term administration of medication.86
There are common human leucocyte antigen associations between periodontal disease and JIA which explains their similar inflammatory effects.
Treatment is aimed at controlling the clinical manifestations by suppressing the articular inflammation and pain, preserving joint mobility and preventing deformity. NSAIDs are used in the early stages. More severe cases are prescribed a variety of medicaments such as gold, methotrexate, corticosteroids and antimalarial drugs. These drugs have their own adverse effects which must be reflected on during orthodontic treatment planning.
Orthodontic considerations in patients with JIA
|
Osteoporosis
Osteoporosis is a common progressive metabolic bone disease that decreases bone density and deterioration of bone structure. Osteoporosis can develop as a primary disorder or secondarily due to some other factor. It is most common in women after menopause, but may develop in men. Risk factors that cannot be altered include advanced age, being female, oestrogen deficiency after menopause,93
and being of European or Asian origin.94
Potentially modifiable risk factors include excessive alcohol intake, vitamin D deficiency, smoking,95
low body mass index,96
malnutrition, physical inactivity97
Osteoporotic bone loss affects cortical and cancellous (trabecular) bone and animal studies have shown this process can result in decreased oral bone density and alveolar bone loss.98
Both bone resorption and formation are accelerated and excessive bone resorption leads to loss of attachment. This theoretically can affect the rate of tooth movement.
Treatment modalities include medication, exercise, a diet sufficient in calcium and vitamin D and lifestyle changes99
In confirmed osteoporosis, bisphoshonate (BP) drugs are the first-line of treatment in women. Oral BPs are poorly tolerated and are associated with oesophagitis. The chronic nature of osteoporosis necessitates long-term administration of BPs and therefore their safety is clinically important and requires some attention. A recent review of the literature identified 26 cases of osteonecrosis of the jaws (ONJ) in patients on oral BPs for the treatment of osteoarthritis.100
This prevalence is relatively low compared with the 190 million patients with osteoarthritis and osteopenia on oral bisphosphonates.101
The main implications on orthodontic treatment are due to BP use and hence these are discussed in the section below.
| Side effects of medication |
|---|
|
|
|---|
Prostaglandins are important mediators in tooth movement and it has been suggested that the use of over-the-counter NSAIDs can affect the efficiency of tooth movement. A study to determine the effect of aspirin, acetaminophen (paracetamol) and ibuprofen on orthodontic tooth movement in rats showed acetaminophen did not affect movement whereas there was a significant difference between the control group and the aspirin and ibuprofen group. The authors suggest paracetamol may be the analgesic of choice in orthodontic patients.102
Their results suggested that NSAIDs reduce the number of osteoblasts by inhibiting prostaglandin synthesis. This led to the use of cyclooxygenase-2 inhibitors (COX-2) drugs, but the effects of these drugs on tooth movement can be very variable. The effects of three different COX-2 inhibitors on tooth movement in Wistar male rats showed that tooth movement was inhibited in rats treated with Rofecoxib. There was, however no significant difference in tooth movement between the control group (saline) and the other two COX-2 inhibitor groups; Celecoxib and Parecoxib.103
Fortunately rofecoxib is now withdrawn from the market due to its cardiotoxicity. Orthodontists should be aware that products from the same class of drugs may have varying effects on orthodontic tooth movement.
Corticosteroids
These drugs are used for many inflammatory and autoimmune diseases. There are two main issues to consider when patients present with a history of corticosteroid use. Firstly, the use of supplemental steroids prior to dental surgery in patients at risk of an adrenal crisis is a contentious issue. The theoretical basis to this practice is that exogenous steroids suppress adrenal function to an extent that insufficient levels of cortisol can be produced in response to stress, posing the risk of acute adrenal crisis with hypotension and collapse. The UK MHRA (Medicines and Healthcare Products Regulatory Agency) and CSM (Committee of Safety of Medicines) together published recommendations in which appear not yet to have been superseded, that include Patients who encounter stresses such as trauma, surgery or infection and who are at risk of adrenal insufficiency should receive systemic corticosteroid cover during these periods. This includes patients who have finished a course of systemic corticosteroids of less than 3 weeks duration in the week prior to the stress. Patients on systemic corticosteroid therapy who are at risk of adrenal suppression and are unable to take tablets by mouth should receive parenteral corticosteroid cover during these periods.104
In contrast various authors have suggested modified guidelines for the management of patients on steroid medications.105
These authors reported on a number of studies confirming the low likelihood of significant adrenal insufficiency even following major surgical procedures. Patients on long-term steroid medication do not require supplementary steroid cover for routine dentistry, including minor surgical procedures, under LA. Instead the blood pressure should be monitored throughout the procedure with IV hydrocortisone available in the event of a crisis.106
Patients undergoing GA for surgical procedures may require supplementary steroids dependent upon the dose of steroid, duration of treatment and severity of the planned surgery.105
The second factor to be aware of is that glucocorticoid therapy is known to affect bone turnover. Kalia and coworkers studied the effect of acute and chronic corticosteroid treatment in rats.107
Their results indicate that bone turnover is reduced in subjects on acute corticosteroid treatment and increased in patients on chronic corticosteroid therapy. The authors postulated that it may be wise to postpone orthodontic treatment on patients on acute doses. They also suggested that orthodontic forces should be reduced and checked more frequently in patients on chronic steroid treatment.
Bisphosphonates (BPs)
These drugs are commonly prescribed to manage osteopenia and osteoporosis or to treat hypercalcaemia caused by bone metastasis in cancer patients (see Table 2
). About half of the BP that is resorbed is excreted unchanged by the kidneys; the remainder has a high affinity for bony tissues and a reported half-life of 10 years. BPs inhibit the resorption of trabecular bone by osteoclasts and hence preserve bone density. Although their medical benefits have been proven, there are increasing numbers of side effects that can affect orthodontic treatment including delayed tooth eruption, inhibited tooth movement,108
impaired bone healing, and BP-induced osteoradionecrosis (ONJ) of the jaws. The risk of side effects is greater if the dose is administered intravenously and on a long-term basis.109
|
The pathogenesis of BP associated ONJ is not fully known. One suggestion is that hypodynamic and hypovascular bone is unable to meet an increased demand for repair and remodelling due to physiological stress (mastication), iatrogenic trauma (tooth extraction) or due to odontogenic infection. This can be exacerbated by the following factors:
Radiographic signs include widening of the periodontal ligament space at the molar furcation areas and mottled bone consistent with osteolysis.111
Orthodontic considerations in patients taking BPs
|
Drug induced gingival overgrowth (DIGO)
DIGO affects a proportion of patients on medication for hypertension, epilepsy and the prevention of organ transplant rejection. The clinical signs can vary in severity from minor overgrowth to complete coverage of standing teeth. These effects are compounded by poor oral hygiene but can occur in the absence of plaque.116
Drifting of teeth can also occur resulting in further aesthetic and functional problems for the patient.78
The main drugs that cause DIGO are phenytoin, cyclosporine and calcium channel blockers including nifedipine, diltiazem, and amlodipine.78
There are a few alternatives for reducing gingival overgrowth.117
One possibility is to have the patient placed on a different drug. There is usually spontaneous regression of the gingival hyperplasia provided the oral hygiene is excellent.118
Non-surgical techniques can limit the occurrence of DIGO, reduce the extent of plaque-induced gingival inflammation and reduce the rate of recurrence. In some patients, however the drug is critical to control either their epilepsy, transplant, cardiac condition. In these cases intensive periodontal treatment with excision of the hyperplastic tissue is necessary.
Orthodontic considerations in patients with DIGO
|
| Allergies |
|---|
|
|
|---|
A delayed hypersensitivity reaction (Type IV) usually presents with localized allergic contact dermatitis. It presents with diffuse or patchy eczema on the contact area and may be accompanied initially by itching, redness, and vesicle formation. The reactions are not life threatening but can cause permanent damage if not treated. The face, especially the lips and mouth, is more commonly affected in dental patients who develop a latex allergy.
Orthodontic staff should be trained in how to deal with an anaphylactic shock. Figure 1
illustrates the sequence of steps that have been outlined by the Resuscitation Council (UK).121
|
The immune response to nickel is usually a type IV cell mediated delayed hypersensitivity reaction. The first phase or sensitization to nickel is increasing with the increasing use of jewellery containing the metal. The prevalence of nickel allergy is estimated 11% of all women and 2% of men.122
Re-exposure to nickel can results in contact dermatitis or mucositis and develops over a period of days or rarely up to 3 weeks.123
Fortunately most individuals with nickel allergy do not report reactions to orthodontic appliances containing nickel. A study by Bass and colleagues of 29 subjects (18 female and 11 male) revealed an initial positive skin patch test to nickel sulphate in five female patients only.124
All 29 patients were followed over their fixed appliance treatment. None of the subjects including the positive test patients demonstrated an inflammatory reaction or discomfort as a result of orthodontic treatment. It is postulated that a much greater concentration of nickel in the oral mucosa than the skin is necessary to elicit an immune response. Nickel leaching from orthodontic bands, brackets, stainless steel or Ni–Ti archwires has been shown in vitro to occur within the first week and then decline thereafter.125
Oral fluids, certain foods and fluoride media can corrode and accelerate the leaching process.126
Concerns about sensitising orthodontic patients to nickel are not supported by the literature but there are a few case reports of localized allergic responses attributed to nickel containing orthodontic appliances.127
,128
Oral clinical signs and symptoms of nickel allergy can include the following: a burning sensation, gingival hyperplasia, angular chelitis, labial desquamation, erythema multiforme, periodontitis, stomatitis with mild to severe erythema, loss of taste or metallic taste, numbness, soreness of the side of the tongue.128
Orthodontic considerations in patients with a nickel allergy
|
Latex allergy
The increase in allergic reactions to natural rubber latex over the past two decades has been accredited to the increased use of latex based gloves and universal precautions. Disposable medical gloves, particularly powdered gloves are the main reservoir of latex allergens. Orthodontic elastics used to apply inter-maxillary forces are another potential source of the latex protein. Both type I and type IV hypersensitivity reactions can occur. The prevalence of potential type I hypersensitivity to latex is lower than 1% in the general population and between 6–12% among dental professionals. For the purpose of this review only risks to patients will be discussed.
Patients at risk of allergy are those with a history of atopy such as hay fever; asthma; eczema; contact dermatitis and those with spina bifida.130
Allergies to certain fruits such as banana, avocado, passion fruit, kiwi and chestnut can also indicate a potential latex allergy. They have proteins that are capable of cross-reacting with latex proteins and hence help sensitize the person to latex.131
Clinical tests, of which the skin prick test is considered most accurate, can determine the presence of circulating antibodies to latex. Multiple testing is recommended for increased accuracy of diagnosis.
Definitive diagnosis should be based on the medical history, and a positive skin reaction to specific chemicals present in natural rubber latex.
Orthodontic considerations in patients with latex allergy
|
Latex free orthodontic materials
|
| Eating disorders |
|---|
|
|
|---|
Patients with eating disorders rarely present with problems of compliance. Oral manifestations of eating disorders include dental caries, erosion, dentinal hypersensitivity, salivary gland hypertrophy, raised occlusal restorations and xerostomia.136
Orthodontic considerations in patients with eating disorders
|
| Summary |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
2 Sheller B, Williams B. Orthodontic management of patients with hematological malignancies. Am J Orthod Dentofacial Orthop 1996; 109: 575–80.[CrossRef][Medline]
3 Prendergast BD. The changing face of infective endocarditis. Heart 2006; 92: 879–85.
4 Moreillon P, Que Y-A. Infective endocarditis. Lancet 2004; 363: 139–49.[CrossRef][Medline]
5 Horstkotte D, Follath F, Gutschik E, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J 2004; 25: 267–76.
6 Danchin N, Duval X, Leport C. Prophylaxis of infective endocarditis: French recommendations 2002. Heart 2005; 91: 715–18.
7 Gould FK, Elliott TS, Foweraker J, et al. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2006; 57: 1035–42.
8 Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc. 2008; 139(Suppl): 3S–24S.
9 NICE Short Clinical Guidelines Technical Team. Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures. London: National Institute for Health and Clinical Excellence, 2008.
10 Oliver R, Roberts GJ, Hooper L. Penicillins for the prophylaxis in dentistry. Cochrane Database Systematic Reviews 2004; 2: CD003813.
11 Hobson R, Clark JD. Infective Endocarditis associated with orthodontic treatment: a case report. Br J Orthod 1993; 20: 241–44.[Abstract]
12 Dajani AS. Bacterial endocarditis after minor orthodontic procedures. J Pediatr 1991; 119: 339–40.[Medline]
13 Biancaiello TM, Romero JR. Bacterial endocarditis after adjustment of orthodontic appliances. J Pediatr 1991; 118: 248–49.[CrossRef][Medline]
14 Ahlstedt S. Penicillin allergy – can the incidence be reduced? Allergy 1984; 39: 151–64.[Medline]
15 Misra S, Percival RS, Devine DA, Duggal MS. A pilot study to assess bacteraemia associated with tooth brushing using conventional, electric or ultrasonic toothbrushes. Eur Arch Paediatr Dent 2007; 8: 42–45.[Medline]
16 Lucas VS, Omar J, Vieira A, Roberts GJ. The relationship between odontogenic bacteraemia and orthodontic treatment procedures. Eur J Orthod 2002; 24: 293–301.
17 Burden DJ, Coulter WA, Johnston CD, Mullally B, Stevenson M. The prevalence of bacteraemia on removal of fixed orthodontic appliances. Eur J Orthod 2004; 26: 443–47.
18 Lucas VS, Kyriazidou, Gelbier, Roberts GJ. Bacteraemia following debanding and gold chain adjustment. Eur J Orthod 2007; 29: 161–65.
19 Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 1: coagulopathies from systemic disease. Br Dent J 2003; 195: 439–45.[CrossRef][Medline]
20 Meechan JG, Greenwood M. General medicine and surgery for dental practitioners Part 9: haematology and patients with bleeding problems. Br Dent J 2003; 195: 305–10.[CrossRef][Medline]
21 Committee on Dangerous Pathogens (ACDP) and the Spongiform Encephalopathy Advisory Committee (SEAC). Transmissible spongiform encephalopathy agents: safe working and the prevention of infection. Department of Health, UK, June 2003.
22 Economics and operational research division. Risk assessment for vCJD in dentistry. Department of Health, June 2003.
23 Farrugia A. variant Creutzfeldt-Jakob disease and hemophilia – further guidance on assessing the risks of plasma-derived products for treating hemophilia. World Federation of Hemophilia task force on Transmissible Spongiform Encephalopathies, 2004.
24 Grossman RC. Orthodontics and dentistry for the hemophilic patient. Am J Orthod 1975; 68: 391–403.[CrossRef][Medline]
25 Gupta A, Epstein JB, Cabay RJ. Bleeding disorders of importance in dental care and related patient management. J Canadian Dent Assoc 2007; 73: 77–83.
26 Piot B, Sigaud-Fiks M, Huet P, Fressinaud E, Trossaët M, Mercier J. Management of dental extractions in patients with bleeding disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 247–50.[CrossRef][Medline]
27 Burden D, Mullally B, Sandler J. Orthodontic treatment of patients with medical disorders. Eur J Orthod 2001; 23: 363–72.
28 Van Venrooy JR, Proffit WR. Orthodontics care for medically compromised patients: possibilities and limitation. J Am Dent Assoc 1985; 111: 262–66.[Abstract]
29 Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 331: 1022–23.
30 Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet 2005; 77: 171–92.[CrossRef][Medline]
31 Sergeant G, Sergeant B. Painful crises in sickle-cell disease. Lancet 1996; 347: 1190–91.[CrossRef][Medline]
32 Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358: 1352–69.
33 Michaelson J, Bhola M. Oral lesions of sickle cell anemia: case report and review of the literature. J Mich Dent Assoc 2004; 86: 32–35.[Medline]
34 Alves PV, Alves DK, de Souza MM, Torres SR. Orthodontic treatment of patients with sickle-cell anemia. Angle Orthod 2006; 76: 269–73.[Medline]
35 Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 10: The paediatric patient. Br Dent J 2003; 195: 367–72.[CrossRef][Medline]
36 Forsberg CM, Krekmanova L, Dahlöff G. The effect of growth hormone therapy on mandibular and cranial base development in children treated with total body irradiation. Eur J Orthod 2002; 24: 285–92.
37 Athanassiadou F, Tragiannidis A, Rousso I, et al. Bone mineral density in survivors of childhood acute lymphoblastic leukemia. Turk J Pediatr 2006; 48: 101–04.[Medline]
38 Näsman M, Forsberg CM, Dahllöf G. Disturbances in dental development in long-term survivors after pediatric malignant diseases. Eur J Orthod 1997; 19: 151–59.
39 Dahllöf G, Forsberg CM, Ringdén O, et al. Facial growth and morphology in long-term survivors after bone marrow transplantation. Eur J Orthod 1989; 11: 332–40.
40 Dahllöf G, Huggare J. Orthodontic considerations in the pediatric cancer patients: a review. Semin Orthod 2004; 10: 266–76.[CrossRef]
41 Scully C, Cawson RA. Medical Problems in Dentistry, 5th Edn. Edinburgh: Elsevier Churchill Livingstone, 2005.
42 Dahllöf G, Jönsson A, Ulmner M, Huggare J. Orthodontic treatment in long-term survivors after pediatric bone marrow transplantation. Am J Orthod Dentofacial Orthop 2001; 120: 459–65.[CrossRef][Medline]
43 Levander E, Malmgren O, Eliasson S. Evaluation of root resorption in relation to two orthodontic treatment regimes. A clinical experimental study. Eur J Orthod 1994; 16: 223–28.
44 Sulaiman F, Huryn JM, Zlotolow IM. Dental extractions in the irradiated head and neck patient: a retrospective analysis of Memorial Sloan-Kettering Cancer Center protocols, criteria and end results. J Oral Maxillofac Surg 2003; 61: 1123–31.[CrossRef][Medline]
45 http://www.efanet.org/asthma/index.html
46 McNab S, Battistutta D, Tavernea A, Symons AL. External apical root resorption of posterior teeth in asthmatics after orthodontic movement. Am J Orthod Dentofac Orthop 1999; 116: 545–61.[CrossRef][Medline]
47 de Valk HW, van der Graaf EA. Cystic fibrosis-related diabetes in adults: where can we go from here? Rev Diabet Stud 2007; 4: 6–12.[CrossRef][Medline]
48 Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol 2007; 61: 11–17.[CrossRef][Medline]
49 Ratjen F. Recent advances in cystic fibrosis. Paediatr Respir Rev 2008; 9: 144–48.[CrossRef][Medline]
50 Primosch RE. Tetracycline discoloration, enamel defects, and dental caries in patients with cystic fibrosis. Oral Surg Oral Med Oral Pathol 1980; 50: 301–08.[CrossRef][Medline]
51 Kinirons MJ. The effect of antibiotic therapy on the oral health of cystic fibrosis children. Int J Paediatr Dent 1992; 2: 139–43.[Medline]
52 Fukushima C, Matsuse H, Saeki S, et al. Salivary IgA and oral Candidiasis in asthmatic patients treated with inhaled corticosteroid. J Asthma 2005; 42: 601–04.[CrossRef][Medline]
53 Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 2: respiratory system. Br Dent J 2003; 194: 593–98.[CrossRef][Medline]
54 Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008; 100: 420–25.[Medline]
55 Hutchinson S, Clark S. Multiple sclerosis presenting to the dental practitioner: a report of two cases. Dent Update 2001; 28: 516–17.[Medline]
56 Fiske J, Boyle C. Epilepsy and oral care. Dent Update 2002; 29: 180–87.[Medline]
57 Fiske J, Shafik HH. Downs syndrome and oral care. Dent Update 2001; 28: 148–56.[Medline]
58 Gorlin RJ, Cohen Jr MM, Hennekam RCM. Syndromes of the Head and Neck, 4th Edn. Oxford: Oxford University Press, 2001.
59 Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 16: 165–70.[CrossRef][Medline]
60 Sheller B. Orthodontic management of patients with seizure disorders. Semin Orthod 2004; 10: 247–51.[CrossRef]
61 Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996; 23: 165–75.[CrossRef][Medline]
62 Hassel TM, Burtner AP, McNeal D, Smith RG. Oral problems and genetic aspects of individuals with epilepsy. Periodontol 2000 1994; 6: 68–78.[CrossRef]
63 Sanders B, Weddell JA, Dodge NN. Managing patients who have seizure disorders: dental and medical issues. J Am Dent Assoc 1995; 126: 1641–47.
64 Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22: 117–39.[CrossRef][Medline]
66 Majola MP, McFayden ML, Connolly C, Nair YP, Govender M. Factors influencing phenytoin-induced gingival enlargement. J Clin Periodont 2000; 27: 506–12.[CrossRef][Medline]
67 Fiske J, Griffiths J, Thompson S. Multiple sclerosis and oral care. Dent Update 2002; 29: 273–83.[Medline]
68 Torogulu MS, Bayramoglu O, Yarkin F, Tuli A. Possibility of blood and hepatitis B contamination through aerosols generated during debonding procedures. Angle Orthod 2003; 73: 571–78.[Medline]
69 Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 5: liver disease. Br Dent J 2003; 195: 71–73.[CrossRef][Medline]
70 McCarthy GM, Mamandras AH, MacDonald JK. Infection control in the orthodontic office in Canada. Am J Orthod Dentofacial Orthop 1997; 112: 275–81.[CrossRef][Medline]
71 http://www.diabetes.org.uk/Guide-to-diabetes/What_is_diabetes/What_is_diabetes/
72 Pinhas-Hamiel O, Dolan L, Daniels S, Stanford D, Khowry P, Zeilter P. Increased incidence of non-insulin dependent diabetes mellitus amongst adolescents. J Pediatr 1996; 128: 608–15.[CrossRef][Medline]
73 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care
2004; 27: 1047–53.
74 http://www.diabetes.org.uk/Guide-to-diabetes/Complications/Long_term_complications/
75 Bensch L, Braem M, van Acker K, Willems G. Orthodontic treatment considerations in patients with diabetes mellitus. Am J Orthod Dentofacial Orthop 2003; 123: 74–78.[CrossRef][Medline]
76 Walker MR, Lovel SF, Melrose CA. Orthodontic treatment of a patient with a renal transplant and drug induced gingival overgrowth: a case report. J Orthod 2007; 34:220–228.
77 Dental Practitioners Formulary 1998–2000, British National Formulary No. 36. London: The Royal Pharmaceutical Society of Great Britain and the British Medical Association, 1998.
78 Butterworth C, Chapple I. Drug-induced gingival overgrowth: a case with auto-correction of incisor drifting. Dent Update 2001; 28: 411–16.[Medline]
79 Shirazi M, Khosrowshahi M, Dehpour AR. The effect of chronic renal insufficiency on orthodontic tooth movement in rats. Angle Orthod 2001; 71: 494–98.[Medline]
80 http://www.emedicine.com/radio/byname/juvenile-rheumatoid-arthritis.htm
81 Manners PJ, Diepeveen DA. Prevalence of chronic arthritis in a population of 12-year-old children in urban Australia. Pediatrics 1996; 98: 84–90.
82 Calabro JJ. Juvenile rheumatoid arthritis. Clin Paediatr Med Surg 1988; 5: 57–75.
83 Twilt M, Mobers SM, Arends LR, ten Cate R, van Suijlekom-Smit L. Temporomandibular involvement in juvenile idiopathic arthritis. J Rheumatol 2004; 31: 1418–22.
84 Pederson TK. Clinical aspects of orthodontic treatment for children with juvenile chronic arthritis. Acta Odontol Scand 1998; 56: 366–68.[CrossRef][Medline]
85 Sidiropoulou-Chatzigianni S, Papadopoulos MA, Kolokithas G. Dentoskeletal morphology in children with juvenile idiopathic arthritis compared with healthy children. J Orthod 2001; 28: 53–58.
86 Welbury RR, Thomason JM, Fitzgerald JL, Steen IN, Marshall NJ, Foster HE. Increased prevalence of dental caries and poor oral hygiene in juvenile idiopathic arthritis. Rheumatology 2003; 42: 1445–51.
87 Pederson TK, Grønhøj J, Melsen B, Herlin T. Condylar condition and mandibular growth during early functional treatment of children with juvenile chronic arthritis, Eur J Orthod 1996; 17: 385–94.
88 Callabro JJ. Juvenile rheumatoid arthritis. Clin Pediatr Med Surg 1988; 5: 57–75.
89 Stroustrup P, Kristensen KD, Küseler A, et al. Reduced mandibular growth in experimental arthritis in the temporomandibular joint treated with intra-articular corticosteroid. Eur J Orthod 2008; 30: 111–19.
90 Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 8: Musculoskeletal system. Br Dent J 2003; 195: 243–48.[CrossRef][Medline]
91 Proffit WR. Treatment planning: the search for wisdom. In Proffit WR, White Jr RP (eds.). Surgical Orthodontic Treatment. St Louis: Mosby, 1991, 159.
92 Kjellberg H, Kiliardis S, Thilander B. Dentofacial growth in orthodontically treated and untreated children with juvenile chronic arthritis (JCA). A comparison with Angle Class II division 1 subjects. Eur J Orthod 1995; 17: 357–73.
93 Prestwood KM, Pilbeam CC, Burleson JA, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994; 79: 366–71.[Abstract]
94 Melton LJ. Epidemiology worldwide. Endocrinol Metab Clin North Am 2003; 32: 1–13.[CrossRef][Medline]
95 Wong PK, Christie JJ, Wark JD. The effects of smoking on bone health. Clin Sci 2007; 113: 233–41.[CrossRef][Medline]
96 Shapses SA, Riedt CS. Bone, body weight, and weight reduction: what are the concerns? J Nutr
2006; 136: 1453–56.
97 WHO Scientific Group on the Prevention and Management of Osteoporosis (2000 : Geneva, Switzerland). Prevention and management of osteoporosis : report of a WHO scientific group, 2003, available at: http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf.
98 Ashcraft MB, Southard KA, Tolley EA. The effect of corticosteroid-induced osteoporosis on orthodontic tooth movement Am J Orthod Dentofacial Orthop 1992; 102: 310–19.[CrossRef][Medline]
99 Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002; (3): CD000333. doi:10.1002/14651858.CD000333. PMID 12137611.
100 Pazanias M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548–58.[CrossRef][Medline]
101 Advisory task force on Bisphosphonate-related osteonecrosis of the jaws, Americal Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369–375.[CrossRef][Medline]
102 Arias OR, Marquez-Orozco MC. Aspirin, acetaminophen, and ibuprofen: their effects on orthodontic tooth movement. Am J Orthod Dentofacial Orthop 2006; 130: 364–70.[CrossRef][Medline]
103 de Carlos F, Cobo J, Perillan C, et al. Orthodontic tooth movement after different coxib therapies. Eur J Orthod 2007; 29: 596–99.
104 http://www.mca.gov.uk/ourwork/monitorsafequalmed/currentproblems/volume24may.htm.
105 Gibson N, Ferguson JW. Steroid cover for dental patients on long-term steroid medication: proposed clinical guidelines based upon a critical review of the literature. Br Dent J 2004; 197: 681–85.[CrossRef][Medline]
106 Thomason JM, Girdler NM, Kendall-Taylor P, Wastell H, Weddel A, Seymour RA. An investigation into the need for supplementary steroids in organ transplant patients undergoing gingival surgery: a double-blind, split-mouth, cross-over study. J Clin Periodontol 1999; 26: 577–82.[CrossRef][Medline]
107 Kalia S, Melsen B, Verna C. Tissue reaction to orthodontic tooth movement in acute and chronic corticosteroid treatment. Orthod Craniofac Res 2004; 7: 26–34.[CrossRef][Medline]
108 Igarashi K, Mitani H, Adachi H, Shinoda H. Anchorage and retentive effects of a bisphosphonate (AHBuBP) on tooth movement in rats. Am J Orthod Dentofacial Orthop 1994; 106: 279–89.[CrossRef][Medline]
109 Advisory task force on Bisphosphonate-related osteonecrosis of the jaws, Americal Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369–75.[CrossRef][Medline]
110 Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63: 1567–75.[CrossRef][Medline]
111 Barker K, Rogers S. Bisphosphonate-associated osteor-adionecrosis of the jaws: a guide for the General Dental Practitioner. Dent Update 2006; 33: 270–75.[Medline]
112 Graham JW. Bisphosphonates and orthodontics: clinical implications. J Clin Orthod 2006: 40: 425–28.[Medline]
113 Zahrowski JJ. Bisphosphonate treatment: an orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 2007; 131: 311–20.[CrossRef][Medline]
114 Rinchuse DJ, Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Orthop 2007; 131: 321–26.[CrossRef]
115 Lin JH. Bisphosphonates: a review of the pharmacokinetic properties. Bone 1996; 18: 75–85.[CrossRef][Medline]
116 Chabria D, Weintraub RG, Kilpatrick NM. Mechanisms and management of gingival overgrowth in paediatric transplant patients: a review. Int J Paediatr Dent 2003; 13: 220–29.[CrossRef][Medline]
117 Marvogiannis M, Ellis JS, Thomason JM, Seymour RA. The management of drug-induced gingival overgrowth. J Clin Periodontol 2006; 33: 434–39.[CrossRef][Medline]
118 James JA, Boomer S, Maxwell AP, et al. Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus. J Clin Periodontol 2000; 27: 144–48.[CrossRef][Medline]
119 Boyd RL, Baumrind S, Periodontal considerations in the use of bonds or bands on molars in adolescents and adults. Angle Orthod 1992; 62: 117–26.[Medline]
120 Poley GE Jr, Slater JE. Latex allergy. J Allergy Clin Immunol 2000; 105: 1054–62.[CrossRef][Medline]
121 Working Party of Resuscitation council (UK). Emergency treatment of anaphylactic reactions. Guidelines for health-care providers. January 2008; 20, available at: http://www.resus.org.uk/pages/reaction.pdf
122 Nielson NH, Menne T. Nickel sensitisation and ear piercing in an unselected Danish population. Contact Dermatitis 1993; 29: 16–21.[CrossRef][Medline]
123 Hostynek JJ. Sensitization to nickel: etiology, epidemiology, immune reactions, prevention and therapy. Rev Environ Health 2006; 21: 253–80.[Medline]
124 Bass JK, Fine H, Cisneros GJ. Nickel sensitivity in the orthodontic patient. Am J Orthod Dentofac Orthop 1993; 103: 280–85.[Medline]
125 Barrett RD, Bishara SE, Quinn YK. Biodegradation of orthodontic appliances. Part 1: biodegradation of nickel and chromium in vitro. Am J Orthod Dentofac Orthop 1993; 103: 8–14.[Medline]
126 Schiff N, Boinet M, Morgan L, et al. Galvanic corrosion between orthodontic wires and brackets in fluoride mouthwashes. Eur J Orthod 2006; 28: 298–304.
127 Dunlap CL, Vincent SK, Barker BF. Allergic reaction to orthodontic wire: report of a case. J Am Dent Assoc 1989; 118: 449–450.[Abstract]
128 Noble J, Ahing SI, Karaiskos NE, Wiltshire WA. Nickel allergy and orthodontics, a review and report of two cases. Br Dent J 2008; 204: 297–300.[CrossRef][Medline]
129 Leite LP, Bell RA. Adverse hypersensitivity reactions in orthodontics. Semin Orthod 2004; 10: 240–43.[CrossRef]
130 ADA Council on Scientific Affairs. The dental team and latex hypersensitivity. J Am Dent Assoc 1999; 130: 257–64.
131 Isola S, Ricciardi L, Saitta S, et al. Latex allergy and fruit cross-reaction in subjects who are non atopic. Allergy Asthma Proc 2003; 24: 193–97.[Medline]
132 Hain MA, Longman LP, Field E, Harrison J. Natural rubber latex allergy: implications for the orthodontist. J Orthod 2007; 34: 6–11.
133 Field EA, Longman LP. Guidance for the management of natural rubber latex allergy in dental patients and dental healthworkers. London: Faculty of General Dental Practitioners (UK), The Royal College of Surgeons, 2004.
134 Russell KA, Milne AD, Khanna RA, Lee JM. In vitro assessment of the mechanical properties of latex and non latex orthodontic elastics. Am J Orthod Dentofacial Orthop 2004; 126: 65–70.[CrossRef][Medline]
135 Ashcroft A, Milosevic A. The eating disorders: 1. Current scientific understanding and dental implications. Dent Update 2007; 34: 544–54.[Medline]
136 Neeley WW, Kluemper GT, Hays LR. Psychiatry in orthodontics. Part 1: typical adolescent psychiatric disorders and their relevance to orthodontic practice. Am J Orthod Dentofacial Orthop 2006; 129: 176–84.[CrossRef][Medline]
137 Burke FJT, Bell TJ, Ismail N, Hartley P. Bulimia: implications for the practising dentist. Br Dent J 1996; 180: 421–26.[CrossRef][Medline]
138 Crossley ML, Shearer AC, Mellor AC, Bridgeman AM. Treatment planning for the problem patient: restorative, ethical, legal and psychological perspectives. Dent Update 2001; 28: 241–46.[Medline]
139 Ashcroft A, Milosevic A. The eating disorders: 2. Behavioural and dental management. Dent Update 2007; 34: 612–20.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |